×

Biotech and Pharmaceuticals Life Sciences

  • Aug 17- The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck& Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive...

  • Aug 17- The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck& Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive...

  • MORRIS PLAINS, N.J. _ Immunomedics Inc. on Wednesday reported a loss of $53.3 million in its fiscal fourth quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share. Immunomedics shares have more than doubled since the beginning of the year.

  • TORONTO, Aug 15- Canada's main stock index slipped on Tuesday, with gains for financial stocks offset by losses for oil companies as crude prices fell. Precious metals miners also lost ground as the price of gold pulled back on easing geopolitical tensions over North Korea. Suncor Energy Inc slipped 0.4 percent to C $40.68, and Pembina Pipeline Corp fell 0.9...

  • SAN RAMON, Calif. _ Galena Biopharma Inc. on Monday reported a second-quarter loss of $8.4 million, after reporting a profit in the same period a year earlier. The San Ramon, California- based company said it had a loss of 22 cents per share. Keywords: Galena Biopharma, Earnings Report.

  • THE WOODLANDS, Texas _ Repros Therapeutics Inc. on Monday reported a loss of $2.2 million in its second quarter. The The Woodlands, Texas- based company said it had a loss of 8 cents per share. Keywords: Repros Therapeutics, Earnings Report.

  • PALO ALTO, Calif. _ Eiger BioPharmaceuticals Inc. on Monday reported a loss of $11.1 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.38 per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • Towns in the path of the eclipse hope it will shine on bottom line

    Cities in the 70-mile-wide "Zone of Totality" are bracing for a huge influx of tourists.

  • WALTHAM, Mass. _ Syndax Pharmaceuticals Inc. on Thursday reported a loss of $13.6 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 79 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • CAMBRIDGE, Mass. _ Dicerna Pharmaceuticals Inc. on Thursday reported a loss of $15.2 million in its second quarter. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 61 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • BOSTON _ Pieris Pharmaceuticals Inc. on Wednesday reported a loss of $10.1 million in its second quarter. On a per-share basis, the Boston- based company said it had a loss of 23 cents. Keywords: Pieris Pharmaceuticals, Earnings Report.

  • NEW YORK _ Fortress Biotech Inc. on Wednesday reported a loss of $17.4 million in its second quarter. The New York- based company said it had a loss of 43 cents per share. Keywords: Fortress Biotech, Earnings Report.

  • SOUTH SAN FRANCISCO, Calif. _ Portola Pharmaceuticals Inc. on Wednesday reported a loss of $69.5 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.10 per share. Portola Pharmaceuticals shares have more than doubled since the beginning of the year.

  • RICHMOND, Calif. _ Sangamo BioSciences Inc. on Wednesday reported a loss of $12.5 million in its second quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • LYNBROOK, N.Y. _ BioSpecifics Technologies Corp. on Wednesday reported second-quarter earnings of $2.6 million. BioSpecifics shares have dropped 13 percent since the beginning of the year. Keywords: BioSpecifics Technologies, Earnings Report.

  • AUSTIN, Texas _ Aeglea Biotherapeutics Inc. on Wednesday reported a loss of $6.6 million in its second quarter. On a per-share basis, the Austin, Texas- based company said it had a loss of 47 cents. Keywords: Aeglea Biotherapeutics, Earnings Report.

  • SINGAPORE _ Wave Life Sciences Pte. Ltd. on Wednesday reported a loss of $24.7 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 77 cents per share. Wave Life Sciences shares have declined 25 percent since the beginning of the year.

  • NEW YORK _ Intra-Cellular Therapies Inc. on Wednesday reported a loss of $17.8 million in its second quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 74 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • NEW YORK _ TG Therapeutics Inc. on Wednesday reported a loss of $28.4 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 46 cents per share. TG Therapeutics shares have more than doubled since the beginning of the year.

  • NEW YORK _ Progenics Pharmaceuticals Inc. on Wednesday reported a loss of $16.6 million in its second quarter. The New York- based company said it had a loss of 24 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.